<- Go Home
Axogen, Inc.
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.
Market Cap
$685.6M
Volume
488.9K
Cash and Equivalents
$20.0M
EBITDA
$8.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$151.0M
Profit Margin
74.27%
52 Week High
$21.00
52 Week Low
$9.21
Dividend
N/A
Price / Book Value
6.07
Price / Earnings
-144.83
Price / Tangible Book Value
6.42
Enterprise Value
$725.9M
Enterprise Value / EBITDA
57.58
Operating Income
$1.7M
Return on Equity
4.48%
Return on Assets
0.54
Cash and Short Term Investments
$29.9M
Debt
$70.3M
Equity
$112.3M
Revenue
$203.3M
Unlevered FCF
$9.8M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium